We are live on ! Find out more
CTIC

CTI BioPharma Corp. (DE) Common Stock
CTIC

Delisted

CTIC was delisted on the 23rd of June, 2023.

Back to rankings

92 hedge funds and large institutions have $334M invested in CTI BioPharma Corp. (DE) Common Stock in 2022 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 24 increasing their positions, 18 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

725% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 4

200% more funds holding in top 10

Funds holding in top 10: 2 → 6 (+4)

183% more capital invested

Capital invested by funds: $118M → $334M (+$216M)

46% more funds holding

Funds holding: 63 → 92 (+29)

33% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 18

22% more call options, than puts

Call options by funds: $3.15M | Put options by funds: $2.57M

Holders
92
Holders Change
+29
Holders Change %
+46.03%
% of All Funds
1.45%
Holding in Top 10
6
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+200%
% of All Funds
0.09%
New
33
Increased
24
Reduced
18
Closed
4
Calls
$3.15M
Puts
$2.57M
Net Calls
+$574K
Net Calls Change
+$72K

Top Buyers

Rank Fund Capital Flow
1
LPC
Lion Point Capital
New York
+$12.7M
2
BL
Bleichroeder LP
New York
+$10.8M
3
Millennium Management
Millennium Management
New York
+$5.88M
4
SI
Sofinnova Investments
California
+$5.82M
5
Two Sigma Investments
Two Sigma Investments
New York
+$4.37M

Top Sellers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
-$12.3M
2
ACM
Altium Capital Management
New York
-$5.62M
3
CC
Caxton Corporation
New Jersey
-$5.55M
4
Deutsche Bank
Deutsche Bank
Germany
-$2.89M
5
Renaissance Technologies
Renaissance Technologies
New York
-$728K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$99.8M – – –
BI
2
BVF Inc
California
$41.7M – – –
LPC
3
Lion Point Capital
New York
$25.6M +$12.7M +4,265,951 +349%
SCM
4
Stonepine Capital Management
Oregon
$21.9M -$12.3M -4,115,954 -47%
BL
5
Bleichroeder LP
New York
$18M +$10.8M +3,609,707 +1,444%
Vanguard Group
6
Vanguard Group
Pennsylvania
$16.8M +$682K +228,600 +7%
Millennium Management
7
Millennium Management
New York
$10.2M +$5.88M +1,972,416 +957%
SI
8
Sofinnova Investments
California
$9.12M +$5.82M +1,952,691 New
Two Sigma Investments
9
Two Sigma Investments
New York
$8.49M +$4.37M +1,464,744 +414%
BlackRock
10
BlackRock
New York
$8.37M -$21.3K -7,137 -0.4%
Invesco
11
Invesco
Georgia
$6.55M +$4.19M +1,403,614 New
GTC
12
Ghost Tree Capital
New York
$6.07M +$298K +100,000 +8%
Renaissance Technologies
13
Renaissance Technologies
New York
$5.19M -$728K -244,000 -18%
EI
14
EAM Investors
California
$4.73M +$3.02M +1,011,935 New
Verition Fund Management
15
Verition Fund Management
Connecticut
$4.65M -$447K -150,000 -13%
Two Sigma Advisers
16
Two Sigma Advisers
New York
$4.41M +$1.15M +385,300 +69%
Marshall Wace
17
Marshall Wace
United Kingdom
$4.03M +$2.31M +773,293 +868%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$3.63M +$283K +94,990 +14%
Susquehanna International Group
19
Susquehanna International Group
Pennsylvania
$3.02M -$152K -50,882 -7%
KCM
20
Kennedy Capital Management
Missouri
$2.96M -$284K -95,136 -13%
DMKJ
21
David M. Knott Jr
$2.6M +$1M +335,608 +152%
CSS
22
Cubist Systematic Strategies
Connecticut
$2.48M +$1.59M +531,600 New
EGI
23
EAM Global Investors
California
$2.4M +$1.53M +512,951 New
Goldman Sachs
24
Goldman Sachs
New York
$1.63M +$859K +288,128 +472%
ACM
25
Altium Capital Management
New York
$1.4M -$5.62M -1,885,200 -86%
1
2 3 4

CTIC Hedge Fund Activity: Q1 2022 in Review

92 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q1 2022, worth a combined $334M — up 183% from $118M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new CTIC positions and 4 closed out — a net gain of 29 holders — while 24 added to existing stakes and 18 trimmed.

The largest buyer was Lion Point Capital, adding an estimated $12.7M. The largest seller was Stonepine Capital Management, cutting an estimated $12.3M.

  • 92 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q1 2022, up from 63 in Q4 2021.
  • Funds reported $334M of CTI BioPharma Corp. (DE) Common Stock stock for Q1 2022, up 183% quarter-over-quarter.
  • 33 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q1 2022 and 4 closed out, a net change of +29 holders.
  • The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q1 2022 was Lion Point Capital, an estimated $12.7M added.
  • The largest CTI BioPharma Corp. (DE) Common Stock seller in Q1 2022 was Stonepine Capital Management, an estimated $12.3M sold.

Based on aggregated 13F filings for Q1 2022.